Sunday 11 October 2026
Export all RLYB data to Excel Powerpack
Rallybio Corporation
RLYB Healthcare Biotechnology
In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
17.02
0.03
+0.18%
Follow RLYB
Rallybio Corporation (RLYB) P/E ratio
As of 9 October 2026, Rallybio Corporation (RLYB) trades at a P/E ratio of 2.1×. Over the past ten years it has ranged from 0.0× (June 2026) to 2.1× (September 2026); the current reading is higher than 99% of that period. That is below the Biotechnology industry median of 8.7× and below the Healthcare sector median of 22.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.1×
Ten-year median
0.0×
Current reading's percentile
99
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| EQ Equillium, Inc. compare | n/m |
| CLLS Cellectis S.A. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| RLYB Rallybio Corporation | 2.1× |
| VXRT VAXART, INC. compare | 2.8× |
| ICCC ImmuCell Corporation compare | 114× |
| Biotechnology industry median | 8.7× |
| Healthcare sector median | 22.5× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)